WA-ADAPTIVE-BIOTECH
28.9.2018 13:02:04 CEST | Business Wire | Press release
Adaptive Biotechnologies today announced that Blood , the Journal of the American Society of Hematology (ASH), published online an analysis of patient samples from the Intergroupe Francophone du Myéloma (IFM) 2009 trial. The analysis confirms the value of minimal residual disease (MRD) as a prognostic indicator in multiple myeloma (MM) measured by next-generation sequencing (NGS), using a prior version of Adaptive’s highly sensitive NGS platform to detect the presence of disease before and after maintenance therapy. The analysis looked at the impact of achieving MRD negativity on progression free survival (PFS) and overall survival (OS). MRD status was shown to be prognostic of PFS and OS. Deep assessment of MRD negativity using this assay, defined in the analysis as less than one myeloma cell in 1 million healthy cells (or 10-6 ) was the strongest prognostic factor for PFS, regardless of treatment, cytogenetics (risk factors) or stage of the disease. Achieving and maintaining MRD negativity regardless of treatment, resulted in significantly superior PFS and OS compared to those patients who remained MRD-positive.1
Myeloma is an incurable cancer of the plasma cells that typically develops in the bone marrow. It is the second most common form of blood cancer, affecting 1.5 times more men than women. MRD refers to the small number of cancer cells that can remain in a patient’s body after treatment, which often cause no signs or symptoms, but eventually can lead to recurrence of the disease. These residual cells can be present at very low levels and require highly sensitive tests to identify them. Even very small amounts of MRD during and after treatment can have a profound effect on treatment success and patient outcomes. A test that can reliably determine the presence and amount of MRD at very low levels can be used in clinical trials and in the clinic to predict clinical outcomes, guide management and improve patient care.
“The IFM 2009 analysis demonstrates that MRD is the most important prognostic indicator in myeloma clinical trials when it is measured by a highly sensitive NGS MRD test,” said Hervé Avet-Loiseau, MD, PhD, Head of the Laboratory for Genomics in Myeloma, University Cancer Center Toulouse, and co-corresponding author. “In the study, patients who achieved MRD negativity with NGS MRD testing, which is able to detect a single myeloma cell among 1 million healthy cells, had better outcomes, regardless of treatment, risk factors or disease stage. Given that MRD-negative patients can still relapse, these results demonstrate the importance of evaluating patients at diagnosis and monitoring them throughout treatment and remission, and it suggests this approach could be used to adapt treatment strategies in future clinical trials.”
Study Results
The IFM 2009 study analyzed the relationship between MRD status, OS and PFS between two treatment arms. In the analysis published in Blood , a subset of patients (N=224) were analyzed using NGS MRD testing prior to maintenance and 183 patients were assessed after maintenance. DNA was extracted from frozen bone marrow samples and sequenced using an earlier version of Adaptive’s NGS MRD assay developed by Sequenta Inc., which Adaptive Biotechnologies acquired in January 2015. Since the acquisition, Adaptive has combined the technologies into its current MRD assay known as clonoSEQ® .
MRD negativity was associated with prolonged PFS prior to (P<0.001) and after completion (P<0.001) of maintenance therapy, demonstrating that NGS MRD testing is highly predictive of outcomes. The PFS was significantly longer in patients who achieved and maintained MRD negativity (<10-6 ) than in patients who were MRD-positive (P<0.001). The risk of progression was nearly doubled in patients with an MRD level of 10-6 −10-5 versus those who were MRD negative (<10-6 ) at the start of maintenance therapy (HR=1.94; 95% CI: 1.03 to 3.63; P=0.04) and was almost three-fold higher when MRD was detected after the completion of maintenance therapy (HR= 2.81; 95% CI: 1.50 to 5.24; P=0.001).
Overall survival was also significantly prolonged in MRD-negative patients compared to MRD-positive patients. The overall survival at 4 years after the start of maintenance therapy was 94% among MRD-negative patients, and 79% among MRD-positive patients (HR=0.24; 95% CI:0.11 to 0.54; P=0.001). The overall survival at 3 years after the completion of maintenance therapy was 96% among MRD-negative patients, and 86% among MRD-positive patients (HR= 0.26; 95% CI: 0.10 to 0.68; P=0.008). PFS and OS were significantly superior for patients who had sustained MRD negativity or became MRD-negative at the end of maintenance, indicating the clinical need for measuring MRD over time (P<0.001; P=0.004).
In the IFM 2009 trial, MRD was also assessed using conventional multiparametric flow cytometry, which can detect one myeloma cell in 10,000 healthy cells (10-4 ). Flow results were previously reported in the New England Journal of Medicine. 2 Of the 233 patients who were previously identified as MRD-negative in the IMF 2009 trial by multiparametric flow cytometry, 113 patients (48%) were found to be MRD-positive using NGS MRD testing.
“The IFM 2009 analysis underscores the need for a deeply sensitive, highly accurate and reliable NGS MRD test that can detect and monitor disease burden throughout the treatment continuum. This study adds to the growing body of evidence that MRD is a critical endpoint that should routinely be incorporated into clinical trials and clinical practice to ensure the best patient outcomes,” said Charles Sang, senior vice president of Diagnostics, Adaptive Biotechnologies. “Adaptive remains committed to providing physicians and their patients with a validated, specific and standardized NGS MRD assay that meets regulatory standards and can be used to assess burden of disease and guide disease management for patients living with multiple myeloma.”
MRD is also being examined by the FDA and the EMA as a surrogate or primary endpoint in multiple myeloma and other lymphoid malignancies. The recent FDA review and approval of drugs with MRD included as a clinical endpoint, as well as the agency’s inclusion of MRD in acute lymphoblastic leukemia (ALL) on the recently released list of surrogate endpoints , demonstrates the clinical actionability of MRD and reinforces the need for accurate and standardized NGS MRD testing.3,4
The Adaptive platform uses NGS to precisely identify and monitor MRD in patients throughout treatment and remission with meaningful sensitivity. Determining MRD status with deep sensitivity can help physicians better manage multiple myeloma and other lymphoid malignancies.
About Minimal Residual Disease
Minimal residual disease (MRD), also referred to as measurable residual disease, refers to cancer cells that remain in the body after treatment for patients with lymphoid cancers. These cells can be present at levels undetectable by traditional morphologic methods, microscopic examination of blood, or a bone marrow or a lymph node biopsy.
MRD is used by physicians to detect and monitor disease burden in patients and to inform their treatment decisions. Clinical practice guidelines5,6 recommend assessing MRD at multiple time points during treatment and maintenance in multiple myeloma and acute lymphoblastic leukemia (ALL), and guidelines include next-generation sequencing (NGS) as a recommended testing method. The prognostic value of MRD assessment has been demonstrated in multiple lymphoid cancers.7,8 Controlled trials have shown that even small amounts of disease are profoundly significant for predicting a patient’s long-term clinical outcomes.1,9,10,11,12 Therefore, highly sensitive, standardized molecular technologies are needed for reliable detection of MRD. Measurement of MRD is currently being evaluated as a way to measure efficacy in drug trials, with the potential to expedite the approval of emerging therapies.13
About IFM 2009
The latest clinical data from the IMF 2009 trial was published in the April 6, 2017 issue of New England Journal of Medicine ( N Eng J Med;376:1311-20 ) . The study evaluated the role of transplantation in patients with newly diagnosed myeloma under the age of 66 treated with lenalidomide, bortezomib, and dexamethasone (RVD). The primary endpoint was PFS. Secondary endpoints include OS and MRD assessment using conventional multiparametric flow cytometry (one myeloma cell in 10,000 healthy cells or 10-4 ). NGS MRD testing was not available when the trial was initiated in 2008. Details of MRD assessment using the multiparametric flow cytometry technique have been previously published.2
About the clonoSEQ ® Assay
The Adaptive Biotechnologies clonoSEQ® Assay enables physicians to utilize a molecular, next-generation sequencing-based minimal/measurable residual disease (MRD) detection method. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time.
The clonoSEQ® Assay is regulated under CLIA and has not been cleared or approved by the FDA. The assay should only be used taking into account all available information and should not be used as the sole determinant to guide patient care. Results may vary. False positive or false negative results may occur for reasons including, but not limited to: sample mix up, misidentification, contamination, technical, and/or biological factors.
About Adaptive Biotechnologies
Adaptive Biotechnologies is the pioneer and leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform to researchers and clinicians around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit adaptivebiotech.com .
Herve Avet-Loiseau acts in a consulting capacity with Adaptive.
1 Perrot A, et al. Blood. 2018: blood-2018-06-858613. Adaptive Biotechnologies provided financial support for this study.
2 Attal M, et al. N Engl J Med. 2017;376(14):1311-1320.
3 BLINCYTO (blinatumomab) Full Prescribing Information. Retrieved September 26, 2018 from: https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf
4 DARZALEX (daratumumab) Full Prescribing Information. Retrieved September 26, 2018 from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
5 NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. V.3.2018.
6 NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2018.
7 Wu, D, et al. Clin Cancer Res . 201:20(17):4540-9.
8 Korde N, et al. JAMA Oncol . 2015:1(6):746-54.
9 Dimopoulos MA, et al. N Engl J Med . 2016;375:1319-1331.
10 Pulsipher M, et al. Blood . 2015;125(22):3501-8. Adaptive Biotechnologies provided financial support for this study.
11 Mannis GN, et al. Biol Blood Marrow Transplant . 2016; 22:1030-1036. Adaptive Biotechnologies provided financial support for this study.
12 Logan AC, et al. Biol Blood Marrow Transplant . 2014;20(9):1307-13. Adaptive Biotechnologies provided financial support for this study. Clinician has received compensation to participate in advisory meetings sponsored by Adaptive.
13 Avet-Loiseau H. Am Soc Clin Oncol Educ Book. 2016; 35e425-30.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005070/en/
Contact:
Adaptive Biotechnologies Beth Keshishian, 917-912-7195 media@adaptivebiotech.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release
New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.
Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 08:00:00 CET | Press release
Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu
RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release
RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co
Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release
Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token
NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press release
NETS becomes the first national payment rail to join Ant International’s Agentic Mobile ProtocolNETS and Ant International’s MOU signing signals commitment to deepen the companies’ long-standing collaboration since 2023The partnership aims to deliver comprehensive AI-native merchant solutions to expand reach and lift operational efficiency Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
